Viral Vector Producer Cell Lines: Learning From mAbs

Gene therapy has made significant progress in recent years, with viral vector-based gene delivery being the primary method. However, the current production methods for adeno-associated virus (AAV) vectors, the most commonly used in gene therapy, are insufficient to meet the demand for therapies. To improve viral vector processing, lessons from the production of monoclonal antibodies (mAbs) can be applied. Key areas of focus include cell line development, cell culture process development, vector design, clone selection, media and process optimization, and quality control. Learn how applying bioprocessing knowledge can accelerate the development of viral vector cell lines and improve efficiency in gene therapy manufacturing.